Capital Advisors, Ltd. LLC
Position in BMRN — Biomarin Pharmaceutical Inc
CIK 1597878
SHAKER HEIGHTS, OH
Position in BMRN
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$3,833
-$4,852 QoQ
Shares Held
67
-57.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#503
of 561 holders
Holding Since
Dec 2021
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BMRN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Advisors, Ltd. LLC holds $457,986 across 47 Biotechnology names. BMRN ranks #19 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CDXS |
Codexis, Inc.
|
28,890 | $65,291 | |
| 2 | PCVX |
Vaxcyte, Inc.
|
1,000 | $58,130 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
99 | $49,176 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
162 | $48,766 | |
| 5 | EXEL |
Exelixis, Inc.
|
731 | $39,773 | |
| 6 | VNDA |
Vanda Pharmaceuticals Inc.
|
5,000 | $30,600 | |
| 7 | CGEM |
Cullinan Therapeutics, Inc.
|
1,600 | $29,136 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
295 | $23,390 |
All Filings in BMRN
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,833 | 67 | Shares | Sole | 2026-07-16 | |
| 2025-06-30 | $8,685 | 158 | Shares | Sole | 2025-07-24 | |
| 2024-12-31 | $1 | 11 | Shares | Sole | 2025-02-04 | |
| 2024-03-31 | $436 | 5 | Shares | Sole | 2024-04-18 | |
| 2023-12-31 | $385 | 4 | Shares | Sole | 2024-02-02 | |
| 2023-09-30 | $442 | 5 | Shares | Sole | 2023-10-27 | |
| 2023-06-30 | $1 | 7 | Shares | Sole | 2023-07-26 | |
| 2023-03-31 | $1 | 7 | Shares | Sole | 2023-05-03 | |
| 2022-12-31 | $1 | 7 | Shares | Sole | 2023-02-07 | |
| 2022-09-30 | $1,356 | 16 | Shares | Sole | 2022-11-09 | |
| 2021-12-31 | $88 | 1 | Shares | Sole | 2022-02-08 | |
| No filing history on record for this holder in this stock. | ||||||